Electromed, Inc.·Healthcare
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Healthcare
Medical - Devices
174
2010-08-13
0.32

Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Electromed (ELMD) has delivered strong revenue growth and margin improvement, but faces a highly competitive, fragmented market for its SmartVest product. ELMD lacks a durable moat, with rivals like Tactile Medical and Baxter showing stronger brand recognition, technological advantages, and higher recent growth rates. Scientific evidence questions the comparative efficacy of HFCWO versus alternative airway clearance therapies, undermining the long-term growth thesis for SmartVest.

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.

Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.

Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript

Electromed, Inc. (ELMD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.